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Abstract：The astrocytic glutamate transporters excitatory amino acid transporters 1 and 2 (EAAT1 10 
and EAAT2) play a key role in nervous system function to maintain extracellular glutamate levels 11 
at low levels. In physiology this is essential for the rapid uptake of synaptically released glutamate, 12 
maintaining the temporal fidelity of synaptic transmission. However, EAAT1/2 hypo-expression or 13 
hypo-function are implicated in several disorders, including epilepsy and neurodegenerative 14 
diseases, as well as being observed naturally with aging. This not only disrupts synaptic information 15 
transmission, but in extremis leads to extracellular glutamate accumulation and excitotoxicity. A 16 
key facet of EAAT1/2 expression in astrocytes is a requirement for signals from other brain cell types 17 
in order to maintain their expression.  Recent evidence has shown a prominent role for contact -18 
dependent neuron-to-astrocyte and/or endothelial cell-to-astrocyte Notch signalling for inducing 19 
and maintaining the expression of these astrocytic glutamate transporters. The relevance of this non 20 
cell-autonomous dependence to age- and neurodegenerative disease-associated decline in astrocytic 21 
EAAT expression is discussed, plus the implications for disease progression and putative 22 
therapeutic strategies. 23 
1. Introduction  24 
Glutamate is the predominant excitatory neurotransmitter in the brain, activating post-synaptic 25 
ionotropic N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 26 
acid (AMPA)/kainate receptors. Co-activation of these receptors allows the influx of Na+ ions, which 27 
depolarises the cell’s membrane potential, triggering an action potential. Once released it is important 28 
that glutamate is rapidly cleared, since failure of this has two key consequences. Firstly, it will 29 
continue to stimulate the post-synaptic receptors after the initial signal has been sent, impairing the 30 
detection of the next signal that arrives – akin to a saturation phenomenon, and potentially leading 31 
to cell swelling due to ion influx [1].  Secondly, if this glutamate escapes from the synaptic zone it 32 
was released into it could activate unintended synapses, triggering activity where it should not. 33 
Significantly, if glutamate escapes the synaptic region it can activate extrasynaptic NMDA receptors: 34 
too much Ca2+ influx via these extrasynaptic NMDA receptors induces signalling cascades that 35 
initiate cell death programs [2, 3].  36 
Astrocytes have long been known to be important in promoting the survival of neurons and for 37 
counteracting the toxic effects of glutamate [4-7]. This protection is largely due to their ability to take 38 
glutamate up from the extracellular environment via transporters located on astrocytic membranes, 39 
preventing excitotoxicity and associated oxidative stress [8, 9]. Once inside the astrocytes, glutamate 40 
is then either converted into α-ketoglutarate by glutamate dehydrogenase (GDH) or transaminases 41 
and shunted into the astrocytic TCA cycle, or else converted into glutamine by the enzyme glutamine 42 
synthetase (GS) [10, 11]. Glutamine is not toxic to neurons, and is extruded by the SNAT3 glutamine 43 
transporter into the extrasynaptic space, which can then be taken up by neurons and converted back 44 
into glutamate via the neuronally expressed phosphate-activated glutaminase (PAG), thus 45 
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replenishing pre-synaptic glutamate stores [12-15]. This glutamate recycling pathway is referred to 1 
as the glutamate-glutamine cycle (see Figure 1). 2 
Astrocytic glutamate uptake and recycling is a vital part of CNS function. Key within this 3 
machinery are the two astrocytic glutamate transporters, excitatory amino acid transporters 1 and 2 4 
(EAAT1 and EAAT2), that are responsible for the bulk of glutamate uptake. The astrocytic glutamate 5 
transporters EAAT1 and EAAT2 belong to the solute carrier 1A family of transporters (SLC1A), 6 
which includes two alanine serine cysteine transporters, ACST1 and ACST2, along with the five 7 
excitatory amino acid transporters, EAAT1-5 [16]. The EAATs are electrogenic secondary-active 8 
transporters, using the concentration gradients of their co- and counter-transported ions (Na+, H+ and 9 
K+) to drive the transport of glutamate against its concentration gradient into the cell [17]. Astrocytes 10 
are able to regulate any fluxes in their pH and membrane potential caused by this transport process 11 
through their high expression of membrane K+ channels (especially KIR4.1), their Na+/H+ exchangers 12 
and Na+/NCO3- cotransporters, as well as dissipating charge and ionic changes throughout the 13 
astrocytic network via connexon coupling (see [18] for a recent review on astrocyte physiology).  14 
Unsurprisingly, reductions in the astrocytic glutamate transporters’ expression and function 15 
have been implicated in a number of CNS diseases, particularly epilepsy, along with several 16 
neurodegenerative diseases, as outlined below. It is therefore of interest to understand how these 17 
transporters are functionally regulated, as boosting their expression and function may offer a novel 18 
way to reduce severity and progression of neurodegenerative diseases.  19 
 20 
Figure 1. The glutamate-glutamine cycle. Glutamate (Glu-) released after excitatory transmission is 21 
collected by astrocytic EAAT transporters 1 & 2. The glutamate is then either converted into α-22 
ketoglutarate (α-KG) via glutamate dehydrogenase (GDH) or transaminase reaction and enters the 23 
TCA cycle, or else is converted into glutamine (Gln) by glutamine synthetase (GS). Astrocytes excrete 24 
Gln back into the extracellular environment via the Na+ driven SNAT3 transporter, which is then 25 
taken up by an as yet unconfirmed neuronal Gln transporter. Neurons then convert Gln back to Glu- 26 
via a phosphate-activated glutaminase (PAG) reaction to replenish their vesicular Glu- stores. 27 
2. Glutamate transporters in the brain 28 
Glutamate is found at high concentrations in the brain, at a concentration of approximately 29 
10 – 14 mmol/L depending on region [19, 20]. However, most of this glutamate is kept within 30 
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intracellular compartments, with very low levels maintained in the extracellular fluid (around 1 
3-4 µmol/L in the extracellular space of the hippocampus) [21, 22]. Accordingly, there are numerous 2 
transporter proteins in the brain that are capable of facilitating glutamate transport to ensure that the 3 
right concentration of glutamate is maintained in the right compartment. These transporters fall into 4 
two broad categories: those which are found in intracellular compartments, such as the three 5 
vesicular glutamate transporters (vGLUT1-3) which package glutamate into synaptic vesicles, and 6 
those located on the plasma membrane of cells that can transport glutamate into (or out of) the cell 7 
[1, 23, 24]. The glutamate transporters that are found in the plasma membranes of brain cells consist 8 
of five sodium-dependent co-transporters, and one sodium-independent exchanger [17, 25, 26]. The 9 
sodium-independent exchanger, xCT, is found almost exclusively on astrocytes, but preferentially 10 
transports cysteine into the cell in exchange for extruding a glutamate molecule out of the astrocyte 11 
[27, 28Lewerenz, 2014 #1428, 29]. Due to the need to transport glutamate into cells against its 12 
electrochemical gradient, it is therefore the sodium-dependent class of transporters that are 13 
responsible for quickly sequestering extracellular glutamate back into cells. There are five known 14 
members of this family of transporters, excitatory amino acid transporters 1 – 5 (EAAT1-5).  15 
2.1. The excitatory amino acid transporters 16 
In the early 1970s a high affinity sodium-dependent uptake system for the negatively charged 17 
amino acids L-glutamate and L-aspartate was first described in synaptosomal preparations, which 18 
was hypothesised to be responsible for the accumulation of the putative excitatory neurotransmitter 19 
glutamate into cells [30, 31]. A few years later Balcar and colleagues went on to show that this 20 
glutamate uptake system was also present in glial cells, but not until 1992 were EAATs first purified, 21 
with four independent groups cloning three distinct EAAT family members: Glt-1 (EAAT2), GLAST 22 
(EAAT1), and EAAC (EAAT3) [32-36]. The final two members were cloned in 1995 (EAAT4) and 1997 23 
(EAAT5) [37, 38].  24 
All members of the EAAT family transport L-glutamate into cells under normal conditions using 25 
the electrochemical gradients of Na+ and K+ [1, 17]. The EAAT family of transporters and the sodium-26 
independent exchanger xCT both display high affinity for glutamate transport compared to the three 27 
vesicular glutamate transporters (KM ≈ 2-100 µM for EAAT1-5 and KM ≈ 20-55 µM for xCT versus KM 28 
≈ 1.5-3.5 mM for vGLUT1-3) [37-50]. Although the EAATs have relatively high affinity for glutamate, 29 
enabling them to sequester low concentrations of extracellular glutamate to prevent excitotoxicity, 30 
they interestingly have relatively slow transport cycle times (see Table 1). This problem may in part 31 
be overcome by rapid surface diffusion and transporter trafficking of the EAATs upon glutamate 32 
stimulation [51, 52]. 33 
The different EAAT subtypes are found throughout the body, and within the brain they are 34 
found on different cell types and in different brain regions. Although they all transport glutamate 35 
into cells, each subtype possesses a different degree of chloride permeability, and it appears the 36 
function of each of these subtypes may vary. A summary of the five EAAT transporters is given in 37 
Table 1. Note well, for clarity in this review the transporters encoded by SLC1A3/Slc1a3, 38 
SLC1A2/Slc1a2 and SLC1A1/Slc1a1 will be consistently referred to as EAAT1, EAAT2 and EAAT3, 39 
respectively, independent of species. Rodent EAAT1, EAAT2 and EAAT3 are typically referred to as 40 
GLAST (Slc1a3), Glt-1 (Slc1a2) and EAAC (Slc1a1) in other studies. However, there is high amino acid 41 
homology between human and rodent proteins, with 96% identity shared between human EAAT1 42 
and rat GLAST, 95% identity between EAAT2 and rat Glt-1, and 92% identity between EAAT3 and 43 
rabbit EAAC1 [39].  44 
2.2. Location of excitatory amino acid transporters 45 
The two subtypes EAAT1 (i.e. GLAST) and EAAT2 (i.e. Glt-1) are referred to as the astrocytic 46 
glutamate transporters as they are the only EAAT subtypes expressed on astrocytes, where they are 47 
predominantly found on fine astrocytic processes opposed to glutamatergic synapses [53-55]. EAAT1 48 
is found in astroglia (including the Bergmann and Müller glia) throughout the brain, on which they 49 
are exclusively expressed, and are the primary collectors of glutamate in both the cerebellum and 50 
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retina (via Bergmann and Müller glia, respectively) [56-62]. EAAT2 is the primary glutamate 1 
transporter in all other brain regions, most prominently in the hippocampus and cortex [54, 57]. The 2 
location of EAAT2 is less astrocyte-exclusive, with some evidence suggesting it is also found to a 3 
small degree in neurons, particularly in the hippocampus and retina (see Zhou and Danbolt, 2013 for 4 
discussion). Combined, EAAT1 and EAAT2 make up a significant proportion of the total protein in 5 
the brain, representing ~2.1% of protein in the molecular layer of the cerebellum, 1.6% in the 6 
hippocampal stratum radiatum, and 1% of protein in forebrain tissue, and are by far the most abundant 7 
EAAT subtypes in the CNS [56].  8 
A more recent study using label-free quantitative (LFQ) tandem mass-spectrometry to survey 9 
the regional protein expression of postnatal human brain tissue has confirmed that EAAT1 and 10 
EAAT2 are abundantly expressed in all regions sampled: the cerebellar cortex (CBC), mediodorsal 11 
thalamic nucleus (MD), striatum (STR), amygdala (AMY), hippocampus (HIP), primary visual cortex 12 
(V1C) and the dorsal prefrontal cortex (DFC) [63]. Apart from the cerebellar cortex (where EAAT2 13 
was within the 93rd percentile), EAAT2 was the most abundantly expressed of the transporters across 14 
all regions, sitting in the 97th (MD), 98th (STR, AMY, HIP and DFC) and 99th (V1C) percentile of most 15 
abundant proteins within each region. EAAT1 on the other hand was more abundantly expressed in 16 
the CBC, being in the 99th percentile of expressed proteins, with consistently high, although lower 17 
than EAAT2, expression across other regions: 94th percentile in the AMY, 95th in MD, STR and HIP 18 
and 97th percentile in the V1C and DFC (calculated from supplementary data Table 10 of Carlyle et 19 
al., 2017) [63]. 20 
 21 
 22 
Table 1. Excitatory amino acid transporter family overview. Abbreviations: CBC = cerebellar cortex, 23 
V1C = primary visual cortex, DFC = dorsal prefrontal cortex, MD = mediodorsal thalamic nucleus, 24 
STR = striatum, HIP = hippocampus and AMY = amygdala. References: [64]. 25 
The EAAT3 subtype is exclusively neuronal, and is found on neurons throughout the brain [65, 26 
66]. It typically localises on dendritic spines and not axon terminals, with its highest expression seen 27 
in the hippocampus, at a concentration of 0.013 mg/g [65]. This is 100 times lower than EAAT2 levels 28 
in the same region, so even in the hippocampus it may only contribute modestly to glutamate 29 
clearance. Consistent with these earlier reports, the more recent LFQ mass spectrometry data showed 30 
a relatively low protein abundance of EAAT3 ranging from the 13th percentile in the V1C to the 26th 31 
percentile in the MD, and sitting at just the 21st percentile of abundance in the hippocampus (from 32 
supplementary Table 10, Carlyle et al., 2017)[63]. This is compared to EAAT1 and EAAT2 which were 33 
in the top percentiles of expressed proteins across all regions in these samples (>90th percentile for 34 
both EAAT1/2 in all regions) [63].  35 
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EAAT4 is another neuronally expressed glutamate transporter, however its expression profile is 1 
more restricted than that of EAAT3, being found primarily on Purkinje cells of the cerebellum, with 2 
some sparse expression in certain subregions of the forebrain and midbrain [67, 68]. It represents 3 
about 0.2% of protein in the molecular layer of the cerebellum, which is approximately 10 times less 4 
than the predominant astroglial subtype in this region, EAAT1 (which represents 1.8% of total 5 
cerebellar protein), and similar to EAAT2 levels (0.3% of total protein) [56, 67]. Again, consistent with 6 
these earlier findings, Carlyle and colleagues more recent mass spectrometry data revealed EAAT4 7 
to be most abundantly expressed in the cerebellar cortex, in the 89th percentile of proteins. This is less 8 
than both EAAT1 and EAAT2 in this region, but significantly higher than EAAT4’s expression across 9 
all other regions (8th percentile in HIP, 10th in V1C, 14th in STR and DFC and 19th in MD and AMY), 10 
confirming that EAAT4 is primarily restricted to the cerebellum [63]. The final member of the family, 11 
EAAT5, has only been found in the eye, where it is located on synaptic terminals of retinal rod bipolar 12 
cells as well as rod and cone photoreceptors [38, 69]. Again, the astrocytic EAAT1 subtype is 13 
expressed more strongly in the retina (located on Müller glia) than EAAT5, and there is evidence that 14 
EAAT5 may physiologically act as a chloride channel rather than a glutamate transporter in these 15 
retinal neurons [70, 71]. 16 
2.3. Structure and function of excitatory amino acid transporters – the case for astrocytic EAAT1 and 17 
EAAT2 18 
Given that the glutamate concentration within cells is over 1,000-fold higher than that in the 19 
extracellular space (≈10 mmol/L compared to 4 µmol/L), combined with the fact that glutamate is an 20 
anion carrying -1 charge, transporters responsible for sequestering glutamate must overcome both 21 
concentration- and electrochemical gradients. All EAATs support the transport of L-glutamate as 22 
well as D and L-Aspartate, displaying a relatively high affinity for inward L-glutamate transport, 23 
with reported KM for glutamate ranging from 10-100 µM (see Table 1)[38, 39, 72]. This high affinity 24 
allows the transporters to continue to work efficiently to uptake glutamate under the low 25 
concentrations of the seen in the extracellular space. However, the times to complete one transport 26 
cycle of a glutamate molecule for the EAATs are relatively low, from 10 ms for EAAT3, 60-70 ms for 27 
EAAT1 and 2, >100 ms for EAAT4 and >1,000 ms for EAAT5 [40, 41, 43-45]. Although this may seem 28 
a limitation as glutamate is required to be quickly cleared, the transporters (especially EAAT1 and 29 
EAAT2) are some of the most abundantly expressed proteins in the CNS (see Table 1), and 30 
furthermore appear to undergo rapid surface diffusion and shuttling, helping to overcome 31 
transporter saturation and slow transport cycle times [51{Carlyle, 2017 #1435]}.  32 
The mechanism of EAAT transport was debated for some time, but it has now been established 33 
that the EAATs combine the transport of 1 glutamate molecule with the co-transport of 3 Na+ and 1 34 
H+, whilst counter-transporting 1 K+[32, 73-75]. This has been supported by more recent studies using 35 
the homologous archaeal glutamate transporters GltPh and GltTk whose structures were crystallised 36 
in 2004 and 2013 [76-79]. As a result of this stoichiometry, there is a net +2 charge per molecule of 37 
glutamate transported, facilitating the inward movement of the otherwise negatively charged 38 
glutamate by using the Na+ and K+ electrochemical gradients to drive transport into the cell. This 39 
stoichiometry is estimated to allow the internal glutamate concentration to be in the order of 106 times 40 
greater than the external concentration under physiological conditions, ensuring the transporters 41 
work to take up rather than extrude glutamate under normal conditions where the concentration 42 
differential is only in the order of 103 [1, 19, 20, 22]. The electrogenic nature of EAAT function also 43 
enables their function to be measured by both patch clamp and two-electrode voltage clamp 44 
electrophysiology [80-82]. Although this transporter stoichiometry is believed to be common to all 45 
members of the EAAT family, meaning all EAATs could help facilitate glutamate clearance, there is 46 
a difference between the EAATs. As well as functioning as a transporter, EAATs can also act as 47 
ligand-gated ion channels, with glutamate activation leading to an uncoupled conductance of Cl- 48 
through the channel [37, 40, 41, 83]. However, the level of anion conductance varies largely between 49 
the different subtypes [84]. EAAT4 and EAAT5 display the largest ion conductance, with their Cl- 50 
conductance being greater than that of their glutamate uptake, EAAT1 and EAAT3 have intermediate 51 
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ion conductance, while EAAT2 displays very little conductance at all [26, 37, 38, 41]. Recent work has 1 
suggested that EAAT5 uses this anionic conductance to act as an “inhibitory” glutamate receptor in 2 
retinal cells, hyperpolarising these cells’ membrane potentials following glutamate activation [71, 85, 3 
86]. It is likely that both the EAAT4 and EAAT5 subtypes do not physiologically function as 4 
glutamate uptake systems, but instead act as Cl- channels.  5 
The first support for astrocytic glutamate transporters EAAT1 and EAAT2 being primarily 6 
responsible for glutamate clearance rather than neuronal subtypes came from studies using 7 
autoradiographic localization, which found the bulk of cleared glutamate was seen in glial cells [87, 8 
88]. Electrophysiological recordings later went on to show that this astrocytic glutamate clearance 9 
was mediated by EAAT1 and EAAT2 [89, 90]. Final evidence that it is the astrocytic EAAT1 and 10 
EAAT2 subtypes, and not the neuronal EAAT3, that are responsible for glutamate clearance comes 11 
from knockout studies.  12 
An EAAT2 knockout animal was generated in 1997, which developed lethal seizures resulting 13 
in an 80% death rate by 13 weeks of age, compared to 100% survival in controls [91]. It was found 14 
that there was a slower clearance of synaptically released glutamate in knockout animals, with 15 
neuronal degeneration appearing specifically in the hippocampal CA1 region [91]. In 1998 the group 16 
went on to generate an EAAT1 knockout animal [92]. Unlike the EAAT2 knockout, removal of EAAT1 17 
did not appear to be lethal, and brain development appeared normal. The group focused on the 18 
cerebellum, given that is EAAT1’s prominent region of expression, and found that in EAAT1 19 
knockouts glutamate uptake in this region was nearly half that of wild-types. Although finding no 20 
difference in basic motor tasks, they found a significant impairment in the knockouts’ ability to 21 
complete a more challenging rotor-rod experiment. Further, they found that mutant EAAT1 animals, 22 
but not wild-types, were susceptible to cerebellar edema following cold injury [92]. Inevitably, in 2006 23 
the group reported on a double EAAT1/EAAT2 knockout animal. Unlike the single mutants, the 24 
double knockout of EAAT1 and EAAT2 was embryonic lethal, with mice dying by E17-18, and brain-25 
wide abnormalities in structure observed [93]. These studies highlight the vital importance of these 26 
transporters in the CNS. 27 
In 1997 a second group generated a mouse knockout for the neuronal glutamate uptake 28 
transporter, EAAT3 [94]. Contrary to the neurological deficits seen in EAAT1 or EAAT2 knockout 29 
animals, removal of EAAT3 had no negative effect on brain formation or function over a period of 30 
>12 months. There was no impairment in motor skills, nor in memory, nor in susceptibility to induced 31 
seizures [94]. A limitation of all these studies, particularly for the EAAT2 knockout, is that they 32 
utilised global knockout models, and not astrocyte specific. As EAAT2 is reportedly expressed on 33 
neurons, this does not rule out neuronal EAAT2 glutamate uptake as being an important source of 34 
glutamate clearance to prevent excitotoxicity. Addressing this limitation, Rosenberg and colleagues 35 
produced conditional neuronal and conditional astrocytic EAAT2 knockout lines [95]. Whilst 36 
neuronal knockouts showed no difference in growth and lifespan, astrocytic EAAT2 mutants had 37 
lower weight gain and significantly higher mortality rates compared to controls [95]. In proteo-38 
liposome preparations from forebrains they found glutamate uptake in astrocytic mutants was 25% 39 
of that in controls, whereas there was no difference in glutamate uptake in these preparations 40 
between neuronal knockouts and controls. EEG recordings further showed astrocytic EAAT2 41 
knockouts to have significantly more seizure events than controls, with no difference between the 42 
conditional neuronal knockouts and controls [95].  43 
Altogether, the evidence shows that it is EAAT1 and EAAT2 expressed on astrocytes that are 44 
primarily responsible for clearing extracellular glutamate to prevent excitotoxicity. The stoichiometry 45 
of the EAAT transporters provides one explanation for why astrocytes and not neurons are primarily 46 
responsible for glutamate homeostasis: uptake can result in significant depolarisation (up to 2+ 47 
charge per molecule). If neurons were required to take up the bulk of released glutamate, this process 48 
in itself would cause significant neuronal depolarisation, potentially leading to a hyper-excitable 49 
feedback loop. Additionally, uptake would result in a significant increase in internal Na+ 50 
concentration, which is counterproductive to the neuron’s need to remove internal Na+ following an 51 
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action potential and could represent a metabolic strain on the neurons and impede their ability to 1 
sustain action potential firing. 2 
3. Astrocytic EAAT regulation 3 
Before the different EAAT isoforms were isolated, it was observed that culturing cerebellar 4 
astrocytes in the presence of cortical neuronal conditioned media increased glutamate uptake [96]. 5 
Over a decade later, astrocytic EAAT1 and EAAT2 were first found to be significantly downregulated 6 
in the striatum following glutamatergic denervation, and the following year it was reported that 7 
EAAT1 was upregulated in cortical astrocyte cultures following activation of astrocytic AMPA and 8 
kainate receptors  [97, 98]. These reports implicated a role for neurons and neuronal activity in 9 
regulating astrocytic glutamate transporters. Following on from this work, Swanson and colleagues 10 
cultured cortical astrocytes alone or in the presence of cortical neurons, finding that isolated 11 
astrocytes expressed very low levels of EAAT1 and EAAT2, that was robustly induced by neuronal 12 
co-culture [99]. It was further documented by Gegelashvili and colleagues that physical culture of 13 
neurons with cortical astrocytes increased astrocytic EAAT1 expression, as well as inducing EAAT2 14 
expression [100]. Additionally, the group showed that feeding pure cortical astrocytes with neuronal 15 
conditioned media was able to induce EAAT2 expression in astrocytes, although they did not find 16 
EAAT1 to be affected by conditioned media. They concluded from this work that a neuronally 17 
released soluble factor was responsible for the regulation of EAAT2, whereas contact mediated 18 
interactions were predominant in the regulation of EAAT1 [100]. Interestingly, this group had earlier 19 
reported that glutamate was able to increase cortical astrocytic EAAT1 expression, suggesting soluble 20 
factors could play a role in regulating this transporter as well [98]. Work since then has focused on 21 




Table 2. Regulation of astrocytic glutamate transporters. References: Hardingham lab unpublished 26 
data, [97-109] 27 
3.1. Regulation of EAAT expression by soluble factors 28 
3.1.1. Cyclic AMP signalling 29 
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One of the first chemicals shown to induce glutamate transporter function in astrocytes was the 1 
cyclic AMP analogue, dibutyryl cyclic AMP (db-cAMP) [110]. Primary astrocytes grown alone 2 
showed little response to glutamate and appeared flat, whilst astrocytes fed with db-cAMP became 3 
more morphologically complex with significantly greater glutamate uptake [98, 110, 111]. As a result, 4 
many researchers began to treat astrocyte cultures with db-cAMP as standard practice, to make them 5 
more reminiscent of their in vivo counterparts. This suggests that one potential mechanism for the 6 
neuronal regulation of astrocytic glutamate transporters is through an induction of the astrocytic 7 
cAMP signalling pathway.  8 
Further evidence for a role of cAMP signalling in astrocytic EAAT regulation comes from studies 9 
showing that application of the adenyl cyclase activator forskolin, to stimulate cAMP production, to 10 
both astrocyte cultures and striatal homogenates is able to increase glutamate uptake [102, 112]. The 11 
mechanism behind this cAMP induced upregulation is less clear, with one group finding inhibition 12 
of cAMP’s downstream target of protein kinase A (PKA) to be sufficient to block the effects of 13 
forskolin, whilst others found an effect of PKA inhibition in pure astrocyte cultures but no effect on 14 
astrocyte glutamate transporter function when grown in the presence of neurons [102, 112]. The latter 15 
finding suggests that although PKA activation may upregulate EAAT1 and EAAT2 activity in 16 
astrocytes in the absence of neurons, in the presence of neurons this pathway is occluded by other 17 
mechanisms that are responsible for the observed neuronal regulation of astrocytic EAATs. Also 18 
unclear is what neuronally derived factor could be responsible for astrocyte cAMP elevation, since 19 
astrocytes express many adenylate cyclase-activating Gs-coupled receptors. Indeed, different ones 20 
may play a role in different circumstances. 21 
3.1.2. Glutamatergic signalling and EAAT trafficking 22 
Despite early reporting that astrocytic AMPA and kainate receptor activation may upregulate 23 
EAAT expression, and that denervation decreases EAAT2 expression, there still lacks a consensus as 24 
to whether glutamatergic synaptic activity has a role in astrocytic EAAT expression. Both work from 25 
our lab and others have found no effect of pharmacological blockade of neuronal activity on 26 
astrocytic EAAT expression [101, 102]. Contrary to these findings, it has been reported that in 27 
hippocampal astrocyte-neuron co-cultures pharmacological block of synaptic activity does reduce 28 
protein levels of both EAAT1 and EAAT2 [113]. Furthermore, acute kainate injections to induce 29 
seizure activity in rats were seen to initially cause a significant increase in cortical EAAT2 expression, 30 
peaking after 4 hours, before ultimately decreasing below baseline levels (following neuronal death) 31 
[114].  32 
Although glutamatergic signalling’s role in regulating EAAT expression is not yet clear, it has 33 
been observed that glutamate treatment can increase functional astrocytic glutamate clearance, and 34 
that this increase in function is mediated directly by the activation of the astrocytic glutamate 35 
transporters, rather than glutamate receptors [115]. The mechanism for this glutamate mediated 36 
increase in EAAT function was found to be due to an induction of EAAT1 surface expression in 37 
mouse astrocytic cultures, with no change in total transporter protein expression [115]. More recently, 38 
it has been reported by two groups using quantum dot tracking that glutamate treatment increases 39 
astrocytic glutamate clearance via robustly increasing the surface diffusion of EAAT2 in rodent 40 
astrocytes from primary culture, organotypic hippocampal slice and acute slice preparations [51, 52]. 41 
This increase in diffusion, especially in the synaptic region, leads to a faster turnover of unoccupied 42 
transporters thereby enabling more efficient clearance of the perisynaptic glutamate. Indeed, 43 
immobilising the diffusion of EAAT2 was found to alter synaptic kinetics, increasing both the rise 44 
and decay time of spontaneous excitatory postsynaptic currents, although total glutamate clearance 45 
was unaltered [51]. As well as surface diffusion, EAATs also undergo surface trafficking, with 46 
glutamate triggering Ca+-dependent internalization of EAAT2 through endocytosis [116, 117]. On the 47 
otherhand, surface expression of EAAT1 has been shown to be increased by glutamate application, 48 
as well as insulin-like growth factor through phosphatidylinositol-3-kinase signalling, whereas the 49 
ubiquitin ligase neuronal developmentally down regulated gene 4, isoform 2 (Nedd4-2) has been 50 
shown to decrease EAAT1 surface expression [115, 118, 119]. These dynamic mechanisms for 51 
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regulating EAAT surface expression are likely to have a significant impact on the functional 1 
glutamate clearance speed and capacity of astrocytes, especially given the EAATs rather slow 2 
transport cycle times. 3 
3.1.3. Other secreted signals 4 
The EAAT2 transporter is able to be regulated by neuronal secreted factors, and much of the 5 
work investigating EAAT regulation has been focused on EAAT2 in particular [100]. Epidermal 6 
growth factor application has been shown to upregulate EAAT2 expression through activation of NF-7 
κB signalling, with neuron-dependent induction of astrocytic NF-κB having been shown to 8 
upregulate astrocytic EAAT2 expression [103-105]. Additionally, enhanced expression of Pax6, a well 9 
characterized transcription factor in astrocytes and the CNS [120, 121], in pure astrocyte cultures has 10 
been recently shown to induce EAAT2 expression, while knockdown of Pax6 in astrocytes grown 11 
with neurons was seen to strongly repress neuron-induced EAAT2 expression [106]. However, the 12 
authors do not speculate upon the neuronally released factor(s) that may modulate EAAT2 13 
expression through astrocytic Pax6.  14 
3.2. Contact dependent regulation: Notch signalling 15 
In contrast to neuronally released factors, relatively little work had investigated the role of 16 
contact-dependent signalling pathways in neuronal control of astrocytic EAAT1 and/or EAAT2 17 
expression. It has been reasonably well established that unlike EAAT2, neuronal upregulation of 18 
EAAT1 expression is via a contact-dependent mechanism and not through a soluble factor, [122] but 19 
the mechanism remained unclear. Furthermore, it had not been established if contact-dependent 20 
signalling also has a role in EAAT2 regulation.  21 
Notch is an important contact dependent signalling pathway present in astrocytes; in fact, it is 22 
the interaction of Notch ligands expressed on neuronally committed precursor cells with 23 
uncommitted precursors that first initiates the precursors’ development into astrocyte lineage cells 24 
[123]. An overview of the Notch signalling pathway is shown in Figure 2. Briefly, when Notch ligands 25 
(for example Delta and Jagged1 & 2) contact the receptors (Notch1-4) the receptors undergo cleavage 26 
by the enzyme γ-secretase, releasing the Notch intracellular domain (NICD) of the receptor. The 27 
NICD then translocates into the cell nucleus, where it associates with the Notch effector (CBF1) and 28 
Mastermind-like (MAML) to activate transcription, with the Hes and Hey family of genes being well-29 
established examples of NICD/CBF1 target genes [124, 125]. 30 
 31 
Figure 2. The Notch signalling pathway. Notch is a contact dependent signalling pathway. When a 32 
Notch ligand contacts a Notch receptor this initiates a cleavage event through the enzyme γ-secretase, 33 
releasing the Notch intracellular domain (NICD). The NICD then translocates into the cell nucleus, 34 
where it pulls down various proteins, such as MAML, and associates with the Notch effector, CBF1. 35 
This association turns on transcription, with the Hes and Hey family of genes prominent examples of 36 
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genes transcribed by this cascade. The γ-secretase inhibitor DAPT is able to prevent activation of the 1 
Notch signalling pathway as the NICD is unable to be cleaved. 2 
In drosophila only the EAAT1 subtype of high affinity glutamate transporters are found, where 3 
it is located on glia cells. Using this model system it was observed that Notch signalling mediated by 4 
neuronally expressed Delta ligands induced the expression of EAAT1 in glia cells [107]. If this is a 5 
conserved process, these results could suggest a role for Notch signalling not only in allowing 6 
astrocyte cell type differentiation, but also in inducing astrocytic EAAT expression.  7 
Strengthening the case for Notch, our lab recently demonstrated using a mixed-species culture 8 
model that neuron-to-astrocyte Notch signalling was a major regulator of astrocytic Slc1a2 (EAAT2) 9 
and Slc1a3 (EAAT1) expression, functionally boosting glutamate transporter activity in mouse 10 
astrocytes [101].  We also found, by expressing a constitutively active form of CBF1, that driving 11 
canonical notch signaling is sufficient to induce glutamate uptake capacity in astrocytes [101]. 12 
Around the same time, another group found that endothelial cells were likewise able to induce 13 
EAAT1 and EAAT2 expression in mouse astrocytes through contact dependent Notch signalling 14 
[108]. The group has now gone on to show that the endothelial Notch ligands responsible for inducing 15 
the astrocytic Notch signalling pathway, and downstream increases in astrocytic Slc1a2 and Slc1a3 16 
expression, are the two Delta-like Notch ligands, Dll1 and Dll4 [109].  17 
Interestingly,  a link between cAMP signalling and Notch in astrocytes has been reported [126]. 18 
Application of db-cAMP was observed to increase the amount of NICD that translocated into the cell 19 
nucleus, and that either application of the γ-secretase inhibitor DAPT to block NICD cleavage, or 20 
application of the PKA inhibitor H89 to prevent cAMP mediated PKA signalling, was sufficient to 21 
prevent this cAMP induced increase [126]. They confirmed that db-cAMP was able to induce Notch 22 
transcription, first by showing increased CBF1 activity via a luciferase assay. They then demonstrated 23 
that db-cAMP treatment increased both Hes5 gene and Hes5 protein expression, which was also 24 
prevented by inhibition of either Notch (via DAPT application) or PKA (via H89) signalling [126]. 25 
This suggests the possibility that neuron contact-dependent and -independent signaling may 26 
converge on the notch pathway, with neuron secreted factors that boost cAMP signaling potentiating 27 
notch signaling. 28 
3..2.1. Is ongoing Notch signalling required to maintain glutamate uptake capacity? 29 
Having found that Notch signalling was required to functionally increase the activity of the 30 
astrocytic glutamate transporters, a key conceptual question remained for us: is this signalling 31 
required to maintain expression throughout development, or is EAAT expression set after their initial 32 
induction? If constant Notch signalling is required to maintain EAAT activity, then faulty neuronal 33 
Notch signalling could be a cause of impaired astrocytic glutamate clearance and increased 34 
excitotoxicity.  35 
To investigate this possibility, we set up a mature coculture paradigm, growing established 36 
mouse astrocytes in the absence (monoculture, MC) or presence (coculture, CC) of rat neurons for 24 37 
days (to neuron DIV24). The γ-secretase inhibitor DAPT was then applied to some cocultured cells 38 
from the point of neuronal plate down (DIV0) or else after two weeks of astrocyte-neuron coculture 39 
(DIV14) to block Notch signalling either from the outset or after the establishment of functional 40 
astrocytic glutamate transporters had occurred. Astrocyte glutamate transporter function was 41 
assessed by electrophysiological recording of astrocytic EAAT currents both on the 13th day of 42 
coculture with neurons in untreated astrocytes to confirm EAAT functional establishment, and then 43 
again on DIV24 across all conditions. 44 
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 1 
Figure 3. Notch signalling is needed to maintain astrocytic EAAT function. Example traces of EAAT 2 
mediated currents in response to 200 µM L-Asp in i) DIV13 neuronal cocultured (CC) astrocyte, ii) 3 
DIV24 CC astrocyte, iii) DIV24 monocultured (MC) astrocyte, iv) DIV24 CC astrocyte +DAPT from 4 
DIV0, and v) DIV24 astrocyte +DAPT from DIV14. Cells were voltage-clamped at -80 mV and all 5 
recordings were done in the presence of 100 µM AP-5. vi) At DIV24 there was a significantly larger 6 
EAAT mediated response in control CC astrocytes compared to MC astrocytes (p = 0.009, LME 7 
ANOVE, df = 29), as well as CC astrocytes treated with DAPT from either DIV0 or DIV14 (p = 0.028 8 
& 0.027, for DIV0 and DIV14 respectively, LME ANOVA, df = 29).  There was no difference in EAAT 9 
response in CC astrocytes treated with DAPT from DIV0 or from DIV14 after currents had been 10 
established. Recordings were taken from cells across at least 3 independent culture batches. 11 
We found that after two weeks exposure to neurons (DIV13) there was robust induction of 12 
astrocytic glutamate transport activity in astrocytes (Fig. 3 i). As expected, by DIV24 there was 13 
significantly greater EAAT activity in astrocytes cultured in the presence of neurons compared to 14 
astrocytes cultured without neurons (Fig 3 ii & iii). The transport activity of cocultured astrocytes 15 
that had Notch inhibited from the outset was (as expected) lower than untreated cocultured cells, 16 
although some residual transport activity was seen (Fig. 3 iv). Most significantly, the EAAT transport 17 
activity in cocultured astrocytes that had Notch signalling inhibited on DIV14 of coculture (i.e. after 18 
the induction of EAAT function) was indistinguishable from those cells who had Notch signalling 19 
inhibited from the outset (Fig. 3 v & vi, Hardingham lab unpublished data). These data support a 20 
model whereby continuous neuron-to-astrocyte Notch signalling is required in order to maintain 21 
astrocytic glutamate transporter activity. This is consistent with the observation that in astrocytes 22 
isolated ex vivo both EAAT1/2 expression and notch target genes decline in culture compared to their 23 
levels immediately post-isolation [101, 127]. 24 
3.3. Epigenetic regulation of EAATs 25 
There is a growing interest into the role of epigenetic regulation of glutamate transporter 26 
expression in astrocytes, in particular the regulation of EAAT2. Astrocytes express both a number of 27 
epigenetic “writers” – enzymes capable of DNA and histone protein modification usually through 28 
the processes of methylation or acetylation, and “erasers” – enzymes capable of removing the 29 
epigenetic marks i.e. demethylation and deacetylation, allowing for the epigenetic control of 30 
astrocytic gene transcription [128-133]. With respect to the glutamate transporters, it has been shown 31 
that overexpression of the epigenetic “erasers” histone deacetylase (HDAC) 1, 3, 6 and 7 all reduce 32 
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EAAT2 promotor activity, which can be reversed by treatment with HDAC inhibitors [134]. There 1 
are suggestions that altered epigenetic regulation of EAAT expression may be a factor in various 2 
diseases. For example it has been observed that in tissue samples from malignant glioma tumors there 3 
is a near total absence of astrocytic EAAT2 expression, which was explained by the pronounced 4 
hypermethylation of the EAAT2 promotor, resulting in the abolishment of EAAT2 transcription [135, 5 
136]. Treatments to inhibit both DNA methyltransferase (an epigenetic “writer” that causes 6 
epigenetic transcriptional repression) and HDAC (which likewise leads to transcriptional repression) 7 
were successfully able to increase astrocytic EAAT2 expression in these glioma cell lines [135]. These 8 
findings raise the possibility of targeting epigenetic mechanisms as a way of controlling astrocytic 9 
EAAT expression in the context of disease [137]. 10 
4. Astrocytic EAAT in ageing and neurodegenerative disease 11 
As noted above, disruption to glutamate homeostasis has the capacity to disturb synaptic 12 
transmission, and by extension, synaptic connectivity and synaptic plasticity of both the classical and 13 
homeostatic type. [138-141], although direct evidence so far extends to Hebbian, spike timing-14 
dependent plasticity [142]. Given the importance of plasticity in shaping circuits in development, one 15 
can envisage that even mild disruption to astrocyte-mediated glutamate homeostasis may contribute 16 
to deficits in early life brain disorders. Indeed, EAAT2 variants have been associated with cerebral 17 
palsy in pre-term infants [143], and with grey matter deficits and working memory in schizophrenia, 18 
along with altered EAAT1 and EAAT2 mRNA expression seen in some CNS regions of schizophrenic 19 
patients [144-146].. Alterations in astrocytic EAAT expression have further been associated with 20 
attention deficit hyperactivity disorder [147, 148], autism [147, 149] and depressive illnesses [150-152]. 21 
Additionally, given the protective effects of transient, phasic synaptic NMDAR activation, [153, 154], 22 
perturbations which interfere with this are likely to be deleterious. Moreover, aberrant glutamate 23 
homeostasis leads to toxic extrasynaptic NMDAR activation, implicated in the pathophysiology of a 24 
number of disorders [155], including stroke [156], epilepsy [157, 158] Huntington’s disease [159, 160], 25 
and Alzheimer’s disease [161-164]. Though pharmacological inhibition [165], altering 26 
synaptic/extrasynaptic signaling balance [166, 167], or uncoupling extrasynaptic NMDARs from 27 
downstream cascades [168, 169] can mitigate these effects, it is important to understand the situations 28 
that lead to glutamate dyshomeostasis in the first place. A number of accounts have linked astrocytic 29 
glutamate transporter dysfunction both to epilepsy and the neurodegenerative diseases, such as 30 
amyotrophic lateral sclerosis (ALS), multiple sclerosis, Alzheimer’s disease and Parkinson’s disease 31 
(see [170] for a recent review of EAATs in diseases of the CNS). Interestingly, there have been recent 32 
suggestions that decreases in astrocytic EAAT expression may also be a natural feature of ageing in 33 
humans. 34 
 35 





EAAT1/2 function and expression reduced by amyloid β; 
Aberrant EAAT1 expression in AD patient neurons; 
Reduced function and expression of EAAT1 and 2 in hippocampal and 




(ALS) / motor 
neuron disease 
EAAT2 
Impaired Glu uptake in patients with sporadic ALS; 
Reduced EAAT2 protein in tissue from motor regions; 
One reported case of a patient with a mutation in SLC1A2 causing 
reduced EAAT2 activity; 
Familial ALS with SOD1 mutations expected to reduce functional 
EAAT2 protein; 
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Reduced EAAT2 in TLE patients with hippocampal sclerosis; 
Reduced EAAT1 & 2 in treatment resistant TLE patients; 







Increased EAAT1 and EAAT2 mRNA and protein in MS optic nerve, 
with increased glutamate uptake; 
Loss of EAAT1 and EAAT2 in areas surrounding cortical lesions of MS 
patients; 
In rat EAE model cortex, increased EAAT2 mRNA and protein, 
increased EAAT1 mRNA but decreased protein. In rat EAE model 
cerebellum, increased EAAT1 and EAAT2 mRNA, but decreased 









Increased EAAT1 and EAAT2 expression following injection of 
α-synuclein oligomers in mouse striatum; 
Decreased EAAT1 and EAAT2 in rat striatum following dopaminergic 
denervation via MPTP treatment or 6-ODHA induced lesion rat models; 
Reduced glutamate uptake in platelets from PD patients; 






Decrease in EAAT2 mRNA expression in neostriatum of HD patients, 
decrease corresponding to disease severity; 







Increased mRNA expression of EAAT1 in Brodmann’s area (BA)9; 
Increased mRNA expression of EAAT1 and EAAT2 in BA10; 
Increased EAAT1 mRNA and decreased protein in post mortem SCZ 
CNS tissue; 








Reduced mRNA expression of EAAT1 and EAAT2 in anterior 
cingulate, dorsolateral prefrontal cortex, locus coeruleus and 
hippocampus of human MDD patients; 






EAAT1 mRNA expression upregulated; 
Decreased functional EAAT2 in conditional Fmr1 KO mouse astrocytes 







Duplication of SLC1A3 gene observed in clinical case of ADHD; 
SLC1A3 rs1049522 allele significantly associated with ADHD; 
Increased EAAT1 mRNA expression in cerebellar cortex 
[147, 148] 
Chronic pain EAAT2 
Decreased EAAT2 mRNA in rostral ventromedial medulla and spinal 
cord in rodent chronic pain models; 
Administration of EAAT2 antagonist alleviates hyperalgesia in rats; 
[205-209] 
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EAAT1 Caused by mutations in SLC1A3 altering properties of EAAT1 [210] 
 1 
Table 3. CNS diseases and disorders associated with astrocytic glutamate transporter dysfunction 2 
4.1. Epilepsy and EAATs 3 
The first demonstration that increased glutamate concentrations are a feature of epilepsy came 4 
from the results of an in vivo microdialysis investigation into the concentrations of GABA and 5 
glutamate in the hippocampi of epilepsy patients from 1989 to 1992 [211]. The investigators found 6 
that an increase in glutamate concentration appeared in the epileptogenic hippocampus 7 
approximately 1.5 minutes prior to seizure onset, but not in the contralateral hippocampus. At the 8 
onset of seizure glutamate levels became further elevated, with concentrations in glutamate also 9 
beginning to increase in the opposing hippocampus. Ten minutes post seizure the non-epileptic 10 
hippocampus glutamate concentrations had returned to baseline, whereas the epileptic side had 11 
persistently elevated glutamate levels >15 minutes post seizure [211]. The patients went on to receive 12 
surgical resection of the epileptic hippocampus, with microscopy of the removed tissue revealing 13 
moderate to severe pyramidal neuron loss throughout the hippocampal tissue along with reactive 14 
gliosis [211].  15 
Given the deleterious effects of seizure-induced glutamate elevation in epilepsy, later work 16 
investigated the potential role of the glutamate transporters. A reduction in astrocytic EAAT2 17 
expression was found in patients with temporal lobe epilepsy (TLE) that went on to develop 18 
hippocampal sclerosis, but no change was found in EAAT2 expression in patients without neuronal 19 
loss [188, 189]. More recently it was reported that there was a decrease in both EAAT1 and EAAT2 in 20 
epileptic hippocampi of patients with intractable treatment-resistant TLE [190]. It is not known if 21 
reduced astrocytic glutamate transporter function initiates some epileptic disorders or exacerbates it, 22 
or even if it is simply an outcome of prolonged disease in humans. However, animal models have 23 
shown that removal of functional astrocytic EAAT2, and not neuronal EAAT3, is sufficient to cause 24 
lethal epilepsy, demonstrating the possible contribution of astrocytic glutamate transporter 25 
dysfunction or hypo-expression in the development of certain epileptic disorders [91, 212]. 26 
4.2. Neurodegenerative diseases and EAATs 27 
An increasing amount of research has gone into investigating the role of astrocytes and their 28 
glutamate clearance in different neurodegenerative diseases, with some links to disease emerging. 29 
One example is in amyotrophic lateral sclerosis (ALS), a motor neuron disease characterised by 30 
progressive loss of motor neurons in the motor cortex, somatosensory cortex and spinal cord, with 31 
around 90% of cases occurring sporadically and 10% with familial linkage. From 1992 it was 32 
discovered that impaired glutamate uptake in motor regions was a feature of tissue samples from 33 
patients with sporadic ALS, and in 1995 that there was a pronounced reduction specifically in EAAT2 34 
protein levels in these tissue samples [180, 181]. Additionally, one patient with sporadic ALS was 35 
found to have a mutation in the SLC1A2 gene that resulted in an EAAT2 protein with reduced 36 
glutamate transporter activity, suggesting EAAT2 dysfunction may cause some cases of disease [182]. 37 
Familial forms of ALS on the other hand were found to be associated with mutations in the 38 
superoxide dismutase gene (SOD1), with SOD1 mutant protein being shown to reduce functional 39 
EAAT2 protein levels in animal models by initiating the cleavage of EAAT2 by Caspase-3  [183-186]. 40 
Specific deletion of Slc1a2 in the spinal cord of mice was recently shown to be sufficient to lead to 41 
motor neuron degeneration by the fifth month of the mice’s lives [187]. Also of note, motor neurons 42 
carrying the C9ORF72 expansion are also vulnerable to glutamate excitotoxicity [213], underlying the 43 
importance of glutamate homeostasis in this disorder. Finally, in work with our collaborators we 44 
have found that in the P301S tauopathy model mouse [214] which results in motor neuron loss of the 45 
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spinal cord, there is an approximate 35% decrease in Slc1a2 expression in disease mice [101]. It is 1 
unclear if it is reduced EAAT function that leads to initial motor neuron death, or if it is the death of 2 
neurons that leads to the decrease in functional EAAT (perhaps due to reduced contact-dependent  3 
Notch signalling), although a combination of both may be responsible. 4 
Glutamatergic excitotoxicity has been suggested to play a role in PD and other 5 
synucleinopathies, with elevated glutamate levels hypothesized as a potential trigger for 6 
dopaminergic cell death. Most studies into EAAT dysfunction in PD have focused on animal models, 7 
however one human study found that there was reduced glutamate uptake in platelets derived from 8 
PD patients [197]. Many rodent models of PD have shown decreases in both EAAT1 and EAAT2 9 
function and expression, including in the PD mutation TJ-1  mouse model, MPTP injection and 6-10 
ODHA lesion models [195, 196, 198]. However, some animal models have seemingly found the 11 
opposite, including one recent study which found that application of pathological α-synuclein 12 
oligomers to mice in vivo caused an increase in EAAT1 and EAAT2 expression that persisted into the 13 
timepoint when Parkinsonian phenotypes occurred [194]. No functional data for glutamate uptake 14 
in this in vivo setting was provided, and it would be interesting for future studies to investigate 15 
glutamate transporter function in this scenario, as the increase in expression may not necessarily be 16 
accompanied by an increase in functional uptake. One other possibility for these incongruous results 17 
is that astrocytes initially upregulate EAATs in response to α-synuclein oligomers (or their effect on 18 
neuronal activity) to try and reduce the excitotoxic effects, but over time with disease this 19 
upregulation is not sufficient, leading to neuronal loss and eventual reductions in EAAT expression.  20 
As with motor neuron disease, there is interest in the role that glutamate dysregulation may play 21 
in the progression of neurodegeneration in Alzheimer’s disease (AD) and other dementias. From the 22 
1990s it was observed that amyloid β, the main protein found in AD-associated plaques, reduced the 23 
function and expression of EAAT1 and EAAT2 in rat hippocampal and cortical astrocytes [171-173]. 24 
Studies of human tissue samples have found the aberrant expression of both the normally astrocyte-25 
specific EAAT1 transporter and the enzyme glutamine synthetase in subsets of cortical pyramidal 26 
neurons of AD patients, suggesting a marked dysfunction in astrocyte glutamate metabolism [174, 27 
175]. Reduced expression of both EAAT1 and EAAT2 have further been observed in the hippocampi 28 
of patients with AD, alongside a significant decrease in glutamate transporter function in human AD 29 
cortices [176, 177]. Altogether, accumulated evidence suggests that impaired astrocytic glutamate 30 
recycling in the hippocampus and cortex is a feature of dementias and may play a role in the 31 
pathological progression of these disorders.  32 
4.3. Ageing and EAATs 33 
It appears that there may be a natural decline in the expression of astrocytic EAAT transporters 34 
with age. From a dataset produced by Barres and colleagues in 2016, where they reported the gene 35 
expression in astrocytes purified from healthy human CNS tissue (subjects ranging from 8 to 63 years 36 
old), the mean expression of the astrocytic glutamate transporters SLC1A2 and SLC1A3 was 37 
approximately 35% lower in the 6 samples from subjects >40 years old compared to the 6 samples 38 
from subjects <40 years old (see Table 4; Zhang et al., 2016). A decrease in astrocytic (EAAT1 and 39 
EAAT2), but not neuronal (EAAT3) protein has further been observed as a feature in aged rats 40 
compared to younger animals, along with a decrease in Slc1a2  expression seen in aged animals [215-41 
217]. Thus, reduction in glutamate uptake capacity in ageing may contribute to it being by far the 42 
most important risk factor in neurodegenerative diseases. 43 
5. Notch signalling in ageing and disease 44 
If impaired glutamate clearance is a feature of age and disease, and Notch signalling is required 45 
to maintain astrocytic EAAT function, then could impaired Notch signalling also be a feature of 46 
disease and ageing?A key enzyme in the Notch signalling pathway is the γ-secretase enzyme 47 
complex, which is responsible for the cleavage of the Notch intracellular domain, a required step for 48 
the induction of the Notch transcriptional pathway. The γ-secretase enzyme complex is itself 49 
comprised of four membrane proteins: presenilin (PSEN1 and PSEN2), nicastrin (NCSTN), anterior 50 
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pharynx-defective 1 (APH1A and APH1B) and presenilin enhancer 2 (PSENEN) [218]. Impairments 1 
in γ-secretase function have long been associated with Alzheimer’s disease. As well as γ-secretase’s 2 
role in cleaving the NICD, it is also involved in cleavage of the amyloid precursor protein (APP); 3 
increased cleavage of APP into toxic Aβ fragments leads to the production of amyloid plaques, a 4 
characteristic feature of AD [219]. As it turns out, mutations that cause familial early onset AD have 5 
predominantly been found to be in the presenilin component of the γ-secretase complex, PSEN1 and 6 
PSEN2 [220, 221]. These mutations alter the activity of γ-secretase and cause an increase in production 7 
of toxic Aβ fragments. 8 
 9 
 10 
Table 4. Notch pathway and astrocytic EAAT expression in human astrocytes with age There is a 11 
reduction in gene expression for both astrocytic EAAT transporters and Notch pathway associated 12 
genes with age in astrocytes isolated from human tissue. Data from Zhang et al., 2016, supplementary 13 
Table S6. 14 
An early human AD drug trial was run on the broad spectrum γ-secretase inhibitor 15 
semagacestat, with the belief that preventing toxic Aβ and amyloid production would improve 16 
disease outcome. However, the opposite occurred: inhibiting γ-secretase worsened AD progression, 17 
with this worsening eventually attributed to the incidental inhibition of Notch signalling [222, 223]. 18 
In the light of recent findings it is a possibility that one of the consequences of Notch inhibition for 19 
the CNS was reduced glutamate uptake capacity. Of note, presenilin mutations that give rise to early 20 
onset AD and increased pathogenic Aβ production are concurrently found to have a significantly 21 
reduced ability to cleave the NICD, suggesting that although mutant presenilin might enhance 22 
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production of toxic Aβ it also results in loss of Notch activation [224-227]. Again, this raised the 1 
possibility that reduced EAAT1/2 expression may be a feature of these early onset AD variants. 2 
Finally, the same human dataset that saw a reduction in EAAT expression with age likewise 3 
found a significant reduction in Notch pathway genes (including HES5 γ-secretase components) in 4 
aged human samples, as shown in Table 4 [129]. This raises the possibility that natural reductions in 5 
Notch signalling with age in humans could engender vulnerability towards reduced EAAT 6 
expression, increased excitotoxicity and ultimately neurodegeneration.  7 
 8 
 9 
6. Concluding remarks 10 
There is emerging evidence that there are reductions in both astrocytic Notch signalling and 11 
astrocytic glutamate transporter expression with age in humans, and that this may be further 12 
exacerbated in neurodegenerative disease (([129, 176]. As it appears that Notch signalling is required 13 
in order to maintain EAAT expression levels in astrocytes (albeit in a rodent model), it is unsurprising 14 
that the reductions in EAAT expression in ageing appear alongside reductions in Notch activity. It is 15 
also intuitive that there should be further reductions in both Notch signalling and EAAT expression 16 
in astrocytes in neurodegenerative disease, as loss of neurons will lead to loss of contact with 17 
astrocytes, and therefore loss of Notch signalling [101]. It is less clear whether this is a downstream 18 
symptom of disease, or whether disease can be the outcome of reduced Notch or EAAT function in 19 
astrocytes to begin with. Given mutations that alter the function of γ-secretase in such a way that 20 
reduces Notch signalling lead to familial AD it is certainly plausible that disease may in part be due 21 
to reduced EAAT function leading to excitotoxic synapse loss and neurodegeneration, particularly in 22 
patients where increased excitability and glutamate dysregulation are observed [237]. The failed 23 
results of the semagacestat drug trial, that worsened disease progression, certainly hint that blocking 24 
Notch signalling and perhaps reducing EAAT function exacerbate neurodegenerative disease [222, 25 
238].  26 
An involvement of Notch signalling and astrocytic EAAT function would also provide a 27 
pleasing explanation of sporadic cases of AD in humans, and why dementia is not a feature of ageing 28 
in non-transgenic mice: as reductions in Notch signalling and EAAT are natural features of human 29 
(and not so far observed in rodent) ageing, this would mean the aged human brain is particularly 30 
vulnerable to the development of dementia, the time when sporadic dementias typically occur. An 31 
external factor, such as vascular deficits, reducing bioenergetic status of the brain and thus reduced 32 
capacity for energy-expensive glutamate uptake, may exacerbate progression in sporadic 33 
neurodegenerative disease where EAATs are under-expressed. A further possibility for the sporadic 34 
occurrence of AD and inter-patient variability in EAAT expression could be explained by differences 35 
in epigenetic repression of EAAT transcription between individuals. Whether astrocytic Notch or the 36 
modulation of EAAT expression could be manipulated in a specific enough way to avoid the myriad 37 
roles of Notch (or epigenetic regulation) plays elsewhere in the body may however be a major 38 
translational hurdle. 39 
Several questions remain to be investigated. Firstly, although we have seen that Notch signalling 40 
from neurons to astrocytes is required to maintain EAAT function in a rodent cell model, it needs to 41 
be ascertained whether this is the case for human cells. Secondly, investigations into the potential 42 
involvement of impaired Notch signalling (and potentially by extension reduced glutamate clearance 43 
capacity) have effectively stalled following on from the findings that inhibiting the Notch effector in 44 
neurons did not lead to disease in mice [230, 231]. Future studies are needed to determine whether 45 
impairing Notch in astrocytes contributes to disease, and what the downstream transcriptional results 46 
are, for example reduced Slc1a2 and Slc1a3 expression. Finally, although we agree that research into 47 
targeting γ-secretases as a treatment for AD should not be abandoned, perhaps chronic partial γ-48 
secretase inhibition is also not the way forward for most cases of AD [222]. More promising are 49 
treatments that specifically inhibit γ-secretase’s cleavage of APP without altering γ-secretases ability 50 
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to cleave the NICD, such as imatinib, although such treatments are still not answering the question 1 
of Notch and EAAT involvement in disease [239]. A novel way forward could be to instead 2 
investigate the effect of increasing astrocytic γ-secretase activity, or in the case of models based on γ-3 
secretase mutations, specifically boosting Notch signalling in these cells, via direct or indirect 4 
mechanisms [240]. The ability to target drugs to specific cell types is still in its infancy (though see 5 
[241]), but once a cell type and target have been validated, greater attention and investment 6 
invariably results. 7 
 8 
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7. Materials and Methods (for Figure 3) 15 
Tissue cultures and stimulations 16 
Astrocytes and neurons were cultured from E17.5 CD1 mouse and E20.5 Sprague Dawley rat 17 
embryos as previously described [242, 243]. Cortices or spinal cords were dissected, enzymatically 18 
digested with papain and mechanically dissociated using a 5 ml pipette. Mouse cortical and spinal 19 
cord astrocytes were obtained by growing cells at low density in DMEM containing 10% fetal bovine 20 
serum and were passaged twice, using Trypsin (both Life Technologies), and plated onto coverslips 21 
in a 24-well plate. These astrocytes are >99% GFAP positive and <0.1% NeuN positive12. For mixed–22 
species co-cultures, rat neurons were plated on top of a confluent layer of DIV14 mouse astrocytes 23 
and both astrocyte monocultures and astrocyte–neuron co-cultures were subsequently kept in 24 
Neurobasal-A medium containing B27 (both Life Technologies), but devoid of serum. Cultures were 25 
maintained up to DIV24, with regular feeding via 50% media exchanges conducted every 3 days. 26 
During this maintenance the cultured cells were either left untreated, treated with the γ-secretase 27 
inhibitor DAPT (10 µM) from DIV0, or treated with DAPT from DIV14.  28 
Electrophysiological recordings 29 
Cultures were recorded from at either DIV13 (co-cultured astrocytes prior to DAPT application) 30 
or at DIV24 (all conditions), as described [101]. Coverslips containing cortical neurons and astrocytes 31 
were transferred to a recording chamber perfused (at a flow rate of 3–5 ml min−1) with an external 32 
recording solution composed of (in mM): 150 NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, and 10 33 
glucose, pH 7.3 (320–330 mOsm). Patch-pipettes were made from thick-walled borosilicate glass 34 
(Harvard Apparatus, Kent, UK), and when filled with the internal recording solution had tip 35 
resistances of 4–8 MΩ. A KCl-based internal was used, composed of (in mM): KCl 130, glucose 4, 36 
HEPES 10, EGTA 0.1, CaCl2 0.025, and sucrose 20; pH 7.2 with KOH. Astrocytes were voltage-37 
clamped at −80 mV and any cells with a resting membrane potential >−60 mV upon break-in were 38 
discarded. To determine the maximal induced EAAT transport current, 200 µM L-Aspartate was bath 39 
applied followed by the addition of the high affinity EAAT inhibitor TFB-TBOA (20 µM) to ensure 40 
that any L-Aspartate-induced current was mediated by the transporter. AP5 (100 µM) was included 41 
in the external solution of all astrocyte recordings to block the activation of NMDARs by L-Aspartate. 42 
Recordings were at room temperature (21±2 °C) using a Multiclamp 200B amplifier (Molecular 43 
Devices, Union City, CA). Recordings were filtered at 5 kHz and digitized online at 20 kHz via a BNC-44 
2090A/PCI-6251 DAQ board interface (National Instruments, Austin, TX, USA) and analysed using 45 
WinEDR 3.6 software (Dr John Dempster, University of Strathclyde, Glasgow, UK). 46 
Statistical analysis 47 
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Results are given as mean ± standard error of mean (SEM), unless otherwise stated. A linear 1 
mixed effects (LME) analysis of variance (ANOVA) model was run using R statistical software to 2 
assess significance of treatment conditions. This analysis was set up to take variation between the 3 
different cultures into consideration. Each data point was coded for the culture batch it was taken 4 
from, and the variation in results due to week by week culture variation was then incorporated as a 5 
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